Pricing news
Every pricing development we have covered, newest first.
5 dated pricing items. Most recent: Lilly Q2: volume up 60%, realised prices down 13% (2026-08-05).
For context: across 32 tracked tirzepatide telehealth programmes, 17 publish a price we could capture, and the cheapest verified all-in cost is $215 a month at a 10 mg maintenance dose — about $2,580 for a first year. Compounded preparations are not FDA-approved. Prices captured 2026-08-05.
All-in monthly cost at 10 mg
Stories in this category
Lilly Q2: volume up 60%, realised prices down 13%
Zepbound revenue grew well below volume, which means the average price actually paid for branded…
Membership stacking spreads: the advertised price is increasingly not the price
Several programmes now split the charge into medication plus a mandatory platform fee.…
First-month promotional rates published as ongoing prices
A recurring error across round-ups, and the likely origin of several wrong figures.…
Zepbound KwikPen reaches self-pay pricing and retail pickup
The metered pen joins the vial at the same tiers, removing the syringe objection from the brand …
Lilly cuts Zepbound self-pay pricing to $299–$449
The starter dose drops to $299 and higher doses to $449, on a 45-day refill condition most cover…
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.